Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Sramek

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
The New England Journal of Medicine|July 23, 1981
"Loads"J J Sramek, A Khajawall
The American Journal of Psychiatry|February 1, 1982
Glutethimide abuseJ J Sramek, A Khajawall
Revue Neurologique|December 3, 1998
Exploratory studies: implications for drug development in Alzheimer's diseaseN R Cutler, J J Sramek
Expert Opinion on Investigational Drugs|November 4, 2000
Ongoing trials in Alzheimer's diseaseJ J Sramek, N R Cutler
Alzheimer Disease and Associated Disorders|February 24, 2001
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?J J Sramek, N R Cutler
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 27, 2001
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug developmentN R Cutler, J J Sramek
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Ethnicity and antidepressant responseJ J Sramek, E H Pi
Alzheimer Disease and Associated Disorders|January 1, 1995
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study"N R Cutler, J J Sramek
Drugs & Aging|July 17, 1999
Recent developments in the drug treatment of Alzheimer's diseaseJ J Sramek, N R Cutler
The New England Journal of Medicine|March 18, 1993
Tacrine in Alzheimer's diseaseN R Cutler, J J Sramek
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
The New England Journal of Medicine|July 23, 1981
"Loads"J J Sramek, A Khajawall
The American Journal of Psychiatry|February 1, 1982
Glutethimide abuseJ J Sramek, A Khajawall
Revue Neurologique|December 3, 1998
Exploratory studies: implications for drug development in Alzheimer's diseaseN R Cutler, J J Sramek
Expert Opinion on Investigational Drugs|November 4, 2000
Ongoing trials in Alzheimer's diseaseJ J Sramek, N R Cutler
Alzheimer Disease and Associated Disorders|February 24, 2001
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?J J Sramek, N R Cutler
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 27, 2001
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug developmentN R Cutler, J J Sramek
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Ethnicity and antidepressant responseJ J Sramek, E H Pi
Alzheimer Disease and Associated Disorders|January 1, 1995
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study"N R Cutler, J J Sramek
Drugs & Aging|July 17, 1999
Recent developments in the drug treatment of Alzheimer's diseaseJ J Sramek, N R Cutler
The New England Journal of Medicine|March 18, 1993
Tacrine in Alzheimer's diseaseN R Cutler, J J Sramek
Pageof 11